Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
Total raised: $29.07M
Investors 2
| Date | Name | Website |
| - | Femmes Bus... | femmesbusi... |
| - | Crealia | crealia.or... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.06.2021 | - | $11.89M | - |
| 20.03.2017 | - | $17.18M | - |
Mentions in press and media 18
| Date | Title | Description |
| 04.01.2022 | Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region | Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal™ Sibnayal™ will ... |
| 20.12.2021 | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA SibnayalTM eligible for reimbursement by the French public health insurance systemASMR IV: Recognition of the contribution of... |
| 20.12.2021 | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA | Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA SibnayalTM eligible for reimbursement by the French public health insurance systemASMR IV: Recognition of the contribution of... |
| 20.12.2021 | Advicenne Announces Positive Opinion From the French Transparency Commission (HAS) for its Drug Sibnayal™ in dRTA | Regulatory News: Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces is has received a positive opinion fr... |
| 07.12.2021 | Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe | Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe First round of pricing negotiations completed in the United Kingdom TwinPharma and ExCEEd Orphan to commercialize Sibnayal™ in Benelux and Central an... |
| 29.09.2021 | Advicenne : September 29, 2021 - Advicenne Reports 2021 Half Year Financial Results | Advicenne Reports 2021 Half Year Financial Results Paris, France, 29 September 2021 - 7:00AM (CEST) - Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for thos... |
| 02.07.2021 | Advicenne : July 2, 2021 - Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA | Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA Paris, France, 2nd July 2021 - 7 am CEST - Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commer... |
| 02.07.2021 | Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA | Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA Paris, France, 2nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commer... |
| 22.06.2021 | Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10 million | Regulatory News: Advicenne SA (FR0013296746 - ADVIC) (the “Company”), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announced today the lau... |
| 22.06.2021 | Advicenne : June 21, 2021 - Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m | The following pages contain information regarding the share capital increase of Advicenne. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access s... |
Show more